Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers
Patent Number: 8,148,069
Filed: Jan. 3, 2007
Lead Inventor: Carlo Croce, Ohio State University
The invention provides “novel methods and compositions for the diagnosis and treatment of solid cancers,” the patent's abstract states. “The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: pCryptoRNAi
Patent Number: 8,148,144
Filed: March 25, 2009
Lead Inventor: Jon Ander Ochoa de Eribe Casas, Chiba University
The invention, the patent's abstract states, relates to “a vector developed to transform fungi [that] can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi.”
Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases
Patent Number: 8,148,342
Filed: Jan. 11, 2008
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals
“The invention relates to a double-stranded compound, preferably an oligoribonucleotide, [that] down-regulates the expression of a human p53 gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The ... invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases [by] administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.”
Title: Compositions and Methods for Mediating RNAi In Vivo
Patent Number: 8,148,344
Filed: March 26, 2009
Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals
“This invention relates to new formulated lipid particles comprising at least one of a single- or double-stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed, or associated,” the patent's abstract states. “These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung, and muscle where they effect gene silencing.”
Title: Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double-Stranded RNA
Patent Number: 8,148,345
Filed: April 13, 2009
Lead Inventor: Yin-Xong Li, Georgia Health Sciences University Research Institute
“Introduction of double-stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression,” the patent's abstract states.
Title: Combination Anti-HIV Vectors, Targeting Vectors, and Methods of Use
Application Number: 20120076763
Filed: April 29, 2010
Lead Inventor: Joseph Anderson, University of California, Davis
The invention, the patent application's abstract states, comprises “recombinant lentiviral vectors containing ... a lentiviral backbone [made of] essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element.
“In an alternative aspect, the vector also contains polynucleotides encoding TRIMS alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides,” it adds. “The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.”
Title: Vector
Application Number: 20120076823
Filed: June 11, 2009
Lead Inventor: Venugopal Nair, Institute for Animal Health
The invention relates to “a herpes virus vector which comprises a modified genomic sequence encoding a microRNA against a target sequence,” the patent application's abstract states. “The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.”
Title: Polyion Complex of Double-Stranded Ribonucleic Acid
Application Number: 20120076836
Filed: March 31, 2010
Lead Inventor: Yuichi Hori, University of Tokyo
The invention comprises a “delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like,” according to the patent application's abstract.
Title: Methods of Determining Potency of Chemically Synthesized Oligonucleotides
Application Number: 20120077276
Filed: Dec. 5, 2011
Lead Inventor: Walter Lima, Isis Pharmaceuticals
The invention comprises “methods for determining potency of RNAi agents,” the patent's abstract states. “Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-103-2
Application Number: 20120077699
Filed: Nov. 15, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention “provides novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent application's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring [miRNA] levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-29a
Application Number: 20120077700
Filed: Nov. 15, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention “provides novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent application's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring [miRNA] levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: RNAi-Mediated Inhibition of Gremlin for Treatment of IOP-Related Conditions
Application Number: 20120077864
Filed: Oct. 26, 2011
Lead Inventor: Jon Chatterton, Alcon
“RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma, such as normal tension glaucoma and open-angle glaucoma,” the patent application's abstract states.
Title: Compositions and Methods for Treating Pancreatic Cancer
Application Number: 20120077867
Filed: June 8, 2010
Inventor: Murray Korc, Dartmouth College
The invention provides “a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells,” the patent application's abstract states. “The invention is based on the finding that cyclin D1 shRNA molecules are capable of attenuating tumor growth and interfering with tumor angiogenesis.”